Biologics to Treat Substance Use Disorders (eBook)

Ivan D. MontoyaNational Institutes of Health, Bethesda, USA

IntroductionBiologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes Phil Skolnick Section 1.  Vaccines  Therapeutic Vaccines for Treating Nicotine Addiction. Matthew W. Kalnik, Ph.D. Vaccines for Treating Cocaine Use Disorders Coreen B. Domingo;  Daryl Shorter; Thomas R. Kosten   Vaccines for Opioid Addiction Michael Raleigh and Paul Pentel Vaccines for Methamphetamine Use Disorder Thomas R. Kosten and Therese A. Kosten Vaccine for Cocaine Addiction and HIV infection Timothy Cardozo, Sergey Shmelkov, Kenneth Carr, John Rotrosen, Pedro Mateu-Gelabert, Samuel R. Friedman Section 2. Monoclonal antibodies Monoclonal Antibodies: Introduction S. Michael Owens Anti-cocaine monoclonal antibodies Hanna N. Wetzel, William J. Ball and Andrew B. Norman                                                                        Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for use in Treating Methamphetamine Abuse Michael D. Hambuchen, Misty W. Stevens, Melinda G. Gunnell, W. Brooks Gen-try, and S. Michael Owens Section 3. Enzymes Enzyme-based cocaine pharmacotherapies: Current status and projections for the future.  James H. Woods, Chang-Guo Zhan Viral gene transfer of enzymes W. Steve Brimijoin Cocaine Hydrolases Designed from Butyrylcholinesterase Fang Zheng and Chang-Guo Zhan                                                                                                                     Section 4. Strategies to optimize the development of biologics to treat addictions Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders David F. Havlicek, Jonathan B. Rosenberg, Dolan Sondhi, Ronald G. Crystal and Stephen M. Kaminsky Nanotechnology based nicotine vaccine Petr O. Ilyinskii and Lloyd P.M. Johnston Exploration of DNA nanostructures for rational design of vaccines Xiaowei Liu, Sidney M. Hecht,  Hao Yan, Paul R. Pentel, and Yung Chang Adjuvants for Substance Abuse Vaccines  Frank M. Orson, Berma M. Kinsey, Muthu Ramakrishnan, Reetakshi Arora, Thomas R. Kosten Skin Vaccination against Nicotine Addiction Xinyuan Chen, Ji Wang, Jeffrey H. Wu, and Mei X. Wu Hapten design for anti-addiction vaccine development Karen C. Collins, Kim D. Janda B cell mechanisms underlying vaccine efficacy against drugs of abuse  Marco Pravetoni, Ph.D. prave001@umn.edu Section 5. Practical Considerations Practical considerations for the development of vaccines against drugs of abuse Oscar B. Torres, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice and Gary R. Matyas Ethical Aspects of Biologics to Treat Substance Use Disorders Ivan D. Montoya